Bod Australia has entered into a collaboration agreement with Drug Science UK to assess the efficacy of its MediCabilis product in managing symptoms associated with the long-term impact of Covid-19 (Long Covid).
Long Covid happens when people experience symptoms of Covid-19 and do not fully recover for several weeks or months after the start of their symptoms. The more common symptoms include sleep disturbance, chronic pain, anxiety and fatigue. Currently, there is no treatment.
Bod’s MediCabilis is used to treat conditions including pain and anxiety and the company is confident it may be effective in treating Long Covid.
As part of the agreement, Bod and Drug Science will progress a UK-based clinical study to explore the effectiveness of prescribing MediCabilis to Long Covid sufferers. Protocol for the study, which is expected to start in the next few months, is still being finalised.
In the UK, it is estimated one in 10 people who test positive for the disease still suffer from symptoms 12 weeks later and one in five have Long Covid symptoms for five weeks or more.